EVT.BRN Stock Chart & Stats
CHF4.63
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF3.85 - CHF27.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
CHF558.43M
Enterprise ValueCHF898.74
Total Cash (Recent Filing)CHF465.59M
Total Debt (Recent Filing)CHF475.87M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Nov 05, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding177,909,560
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.19
Price to Sales (P/S)1.23
P/FCF Ratio-11.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.67Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.1
Revenue Forecast (FY)CHF564.49M
Bulls Say, Bears Say
Bulls Say
Diversified Partnered Revenue ModelThe combination of recurring research services and contingent milestone or royalty economics can diversify revenue sources and provide operating leverage if partnered programs advance, supporting longer-term participation in drug-development value creation.
Integrated Drug Discovery PlatformBroad capabilities across the drug-development workflow can deepen customer relationships, increase project scope and reduce reliance on a single research service. This integrated positioning may support repeat business as partners seek coordinated development expertise.
Manageable Headline LeverageDebt is not excessive relative to reported equity, giving Evotec some financial capacity to operate its platform and fund development activities. This provides a buffer, although ongoing losses remain important to balance-sheet resilience.
Bears Say
Sustained UnprofitabilityPersistent operating and net losses indicate that the current business scale is not yet converting research activity into sustainable earnings. Continued deficits could constrain investment, weaken negotiating flexibility and increase dependence on external funding.
Negative Cash GenerationCash consumption reduces the resources available to fund platform investment and pipeline development internally. If negative cash generation persists, Evotec may need financing, asset monetisation or spending reductions that could limit strategic flexibility.
Margin And Revenue DeteriorationContracting revenue combined with materially lower gross margins suggests pressure from project mix, pricing or delivery costs. Without a durable recovery, weaker contribution from each research dollar can delay operating leverage and prolong losses.
EVT.BRN FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest stock price was CHF3.85 and its highest was CHF27.76 in the past 12 months.
What is Evotec’s market cap?
Evotec’s market cap is CHF558.43M.
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Evotec’s earnings last quarter?
Evotec released its earnings results on Aug 13, 2026. The company reported -CHF0.244 earnings per share for the quarter, missing the consensus estimate of -CHF0.066 by -CHF0.178.
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -0.44.
How many shares outstanding does Evotec have?
Evotec has 177,909,560 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Evotec reported an EPS of -CHF0.244 in its last earnings report, missing expectations of -CHF0.066. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in CH:EVT.BRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.67 (― Downside)
CHF5.67 (― Downside)
Insider Transactions
Sold Shares
Worth CHF541.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Evotec
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
EVT.BRN Stock 12 Month Forecast
Average Price Target
CHF5.67
Biofrontera
―
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Merck KGaA
―
Heidelberg Pharma AG
―